Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Fig. 2

Patients with IP week 24 response who achieved weeks 40 and 52 responses. ABA, abatacept; DAS28 (CRP), Disease Activity Score in 28 joints using C-reactive protein; IP, induction period; MTX, methotrexate; PBO, placebo; SDAI, Simplified Disease Activity Index. aPercentages based on number of patients within each treatment group who achieved response at IP week 24 (denominator). Previously presented at EULAR 2020 (poster FRI0090); copyright © the authors

Back to article page